European Commission approves Novartis’ Itvisma to treat SMA
The European Commission has granted approval for Novartis’ Itvisma (onasemnogene abeparvovec) as a treatment for children two years…
European Commission approves Novartis’ Itvisma to treat SMA
The European Commission has granted approval for Novartis’ Itvisma (onasemnogene abeparvovec) as a treatment for children two years…
Novartis Secures Positive EU Backing for SMA Gene Therapy Itvisma
medical research 15 ©The U.S. National Archives Novartis (NYSE:NVS) said the European Medicines Agency’s Committee for Medicinal Products…